Literature DB >> 24649571

Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery.

Javier Suárez Cuenca, Pilar Gayoso Diz, Francisco Gude Sampedro, J Marcos Gómez Zincke, Helena Rey Acuña, M Manuela Fontanillo Fontanillo.   

Abstract

Activated clotting time (ACT) has been used to monitor coagulation and guide management of anticoagulation control in patients undergoing cardiac surgery for decades. However, reversal of heparin with protamine is typically empirically based on total heparin administered. Dose-related adverse effects of protamine are well described. The aim of this study was to evaluate a heparin reversal strategy based on calculation of the protamine dose based on ACT measurements. We present a method using a mathematical formula based on the dose-response line (1). To check the formula, we performed a retrospective observational cohort study of 177 patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The study group of 80 patients was administered the dose of protamine obtained using our formula, and the control group of 97 patients was administered the empirically calculated dose. The ACT returned to normal values in patients who were given doses of protamine that were calculated using our formula; all but two had a final ACT of 141. The application of the formula resulted in a significant reduction in the dose of protamine (p < .023). The formula we present is a valid method for calculating the dose of protamine necessary to neutralize heparin. This same method can be used working with a target ACT to adjust the dose of heparin. As a result of its functionality, it allows application on a daily basis standardizing the process. We believe that the formula we developed can be applied in all those procedures in which it is necessary to anticoagulate patients with heparin and later neutralization (cardiac surgery with or without CPB, vascular surgery, procedures of interventional cardiology, and extracorporeal depuration procedures).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24649571      PMCID: PMC4557496     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  21 in total

1.  Successful use of a reduced dose of protamine after cardiopulmonary bypass.

Authors:  A V Guffin; R W Dunbar; J A Kaplan; J W Bland
Journal:  Anesth Analg       Date:  1976 Jan-Feb       Impact factor: 5.108

2.  Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions.

Authors:  Robert L Lobato; George J Despotis; Jerrold H Levy; Linda J Shore-Lesserson; Melvin O Carlson; Elliott Bennett-Guerrero
Journal:  J Thorac Cardiovasc Surg       Date:  2010-03-19       Impact factor: 5.209

3.  [Comparison of two schemes of administering the Russian protamine sulfate after extracorporeal circulation in cardiosurgical patients].

Authors:  M A Charnaia; Iu A Morozov; V G Gladysheva; A M Isaeva
Journal:  Anesteziol Reanimatol       Date:  2006 Sep-Oct

4.  [Impact of protamine sulfate on hemostasis system after operations with artificial circulation].

Authors:  M A Charnaia; T V Klypa; Iu A Morozov; N P Shmerko; V G Gladysheva; A A Andriianova
Journal:  Khirurgiia (Mosk)       Date:  2007

Review 5.  Management of bleeding and coagulopathy after heart surgery.

Authors:  B L Milas; D R Jobes; R C Gorman
Journal:  Semin Thorac Cardiovasc Surg       Date:  2000-10

6.  Heparin and protamine titration do not improve haemostasis in cardiac surgical patients.

Authors:  L Shore-Lesserson; D L Reich; M DePerio
Journal:  Can J Anaesth       Date:  1998-01       Impact factor: 5.063

7.  The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph.

Authors:  Nouman U Khan; Charlotte K Wayne; Julian Barker; Timothy Strang
Journal:  Eur J Anaesthesiol       Date:  2010-07       Impact factor: 4.330

8.  The Hemochron Response RxDx heparin and protamine dosing system.

Authors:  Stacy A Jaryno; Marcia L Zucker; Frank M LaDuca
Journal:  J Extra Corpor Technol       Date:  2004-09

9.  Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.

Authors:  T Mochizuki; P J Olson; F Szlam; J G Ramsay; J H Levy
Journal:  Anesth Analg       Date:  1998-10       Impact factor: 5.108

10.  Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study.

Authors:  Marx Runge; Christian H Møller; Daniel A Steinbrüchel
Journal:  J Extra Corpor Technol       Date:  2009-03
View more
  3 in total

Review 1.  Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum.

Authors:  Patrick Hecht; Martin Besser; Florian Falter
Journal:  J Extra Corpor Technol       Date:  2020-03

2.  Can the Minimum Protamine Dose to Neutralize Heparin at the Completion of Cardiopulmonary Bypass be Significantly Lower than the Conventional Practice?

Authors:  Min-Ho Lee; William Riley; Kenneth G Shann
Journal:  J Extra Corpor Technol       Date:  2021-09

3.  Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.

Authors:  Manuela Albisetti; Arno Schlosser; Martina Brueckmann; Savion Gropper; Stephan Glund; Igor Tartakovsky; Leonardo R Brandão; Paul A Reilly
Journal:  Res Pract Thromb Haemost       Date:  2017-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.